Sie sind hier: Startseite Abteilungen Allgemeine Psychologie I Mitarbeiterinnen und Mitarbeiter Ulrich Ettinger

Ulrich Ettinger

UlrichEttinger

 

Prof. Dr. Ulrich Ettinger

Leiter der Abteilung für Allgemeine Psychologie I

Institut für Psychologie
Allgemeine Psychologie I
Kaiser-Karl-Ring 9
D-53111 Bonn

Raum 3.016

Tel.: 0228/73-4208
Fax: 0228/73-62323
Skype: ulrich.ettinger
Email: ulrich.ettinger at uni-bonn.de

 

Sprechstunde: Mo 10:00-11:00 Uhr und nach Vereinbarung

 


BAföG-Beauftragter der Philosophischen Fakultät zur Erteilung von Leistungsbescheinigungen für die Buchstaben A-C

Für Leistungsbescheinigungen können Sie sich in meiner Sprechstunde an mich wenden oder jederzeit per Email einen Termin mit mir vereinbaren.

 

 

Forschungsinteressen

  • Kognitive Psychopharmakologie

  • Okulomotorik

  • Schizophrenie und Schizotypie

  • Schlafentzug
  • Inhibition und Impulsivität

  • Verhaltens- und Molekulargenetik der Kognition sowie Gehirnfunktion und -struktur

 

 

Studium und Werdegang

seit 04/2012: Professor für Psychologie, Institut für Psychologie, Rheinische Friedrich-Wilhelms-Universität, Bonn

01/2009 – 03/2012: Leiter einer DFG Emmy Noether Gruppe, Klinik für Psychiatrie und Department Psychologie, Ludwig-Maximilians-Universität, München

10/2004 – 12/2008: Research Fellow und Lecturer / Senior Lecturer, Centre for Neuroimaging Sciences, Institute of Psychiatry, King’s College London, UK

10/2003 – 09/2004: Richard H. Tomlinson Postdoctoral Research Fellow, Department of Psychology und Douglas Hospital, McGill University, Montreal, Canada

10/2002 – 09/2003: Postdoctoral Research Worker, Division of Psychological Medicine, Institute of Psychiatry, King’s College London, UK

09/1999 – 09/2002: Promotion, Department of Psychology, Goldsmiths College, und Division of Psychological Medicine, Institute of Psychiatry, King's College London, UK

09/1995 - 09/1999: Studium der Psychologie und Neurowissenschaft, Goldsmiths College und King's College London, UK

 

 

Drittmittel

Finanzielle Unterstützung meiner Forschung in Höhe von ca. €2.100.000 eingeworben u.a. von DFG, ESRC, MRC, NIHR, VolkswagenStiftung, Friedrich-Baur-Stiftung, FöFoLe (LMU), British Academy, Leverhulme Trust

 

 

Preise und Auszeichnungen

Psychopharmacology Award, British Association for Psychopharmacology (06/2014)

Lehrpreis der Universität Bonn (06/2013)

Rafaelsen Award, Collegium Internationale Neuro-Psychopharmacologicum (03/2009)

Young Scientist Award, 14th Biennial Winter Workshop on Schizophrenia (11/2007)

Förderpreis, Deutsche Gesellschaft für Biologische Psychiatrie (08/2006)

Young Investigator Award, International Congress on Schizophrenia Research (02/2005)

Travel Award, Organisation for Human Brain Mapping (05/2004)

Young Scientist Award, 12th Biennial Winter Workshop on Schizophrenia (11/2003)

Young Scientist Award, 11th Biennial Winter Workshop on Schizophrenia (11/2001)

Bursary, Department of Psychology (Goldsmiths College), Promotionsstipendium (09/1999)

Studentship, Section of Cognitive Psychopharmacology (Institute of Psychiatry), Promotionsstipendium (09/1999)

Bursary, Department of Neuroscience (Institute of Psychiatry) (10/1998)

Goldsmiths Psychology Prize (09/1998)

 

 

Publikationen

 

Originalarbeiten in referierten Zeitschriften

1.    Petrovsky N*, Ettinger U*, Hill A, Frenzel L, Meyhöfer I, Wagner M, Backhaus J, Kumari V (2014). Sleep deprivation disrupts prepulse inhibition and induces psychosis-like symptoms in healthy humans. Journal of Neuroscience 34(27):9134–9140 * shared first authorship


2.    Mueller S, Costa A, Keeser D, Pogarell O, Berman A, Coates U, Reiser MF, Riedel M, Möller HJ, Ettinger U, Meindl T (in press) The Effects of Methylphenidate on Whole Brain Intrinsic Functional Connectivity. Human Brain Mapping.


3.    Hamm JP, Crawford TJ, Nebl H, Kean M, Williams SCR, Ettinger U (2014). Neural correlates of illusory line motion. PLoS ONE. 9(1):e87595. doi: 10.1371/journal.pone.0087595.


4.    Kambeitz J, Romanos M, Ettinger U (2014). Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. The Pharmacogenomics Journal. 14(1):77-84.


5.    Cutsuridis V, Kumari V, Ettinger U (2014). Antisaccade Performance in Schizophrenia: A Neural Model of Decision Making in the Superior Colliculus. Frontiers in Decision Neuroscience. 8:13. doi: 10.3389/fnins.2014.00013.


6.    Petrovsky N, Ettinger U, Quednow BB, Landsberg MW, Drees J, Lennertz L, Frommann I, Heilmann K, Sträter B, Kessler H, Dahmen N, Mössner R, Maier W, Wagner M (2013). Nicotine enhances antisaccade performance in schizophrenia patients and healthy controls. International Journal of Neuropsychopharmacology. 16(7):1473-81.


7.    Petrovsky N, Ettinger U, Kessler H, Mössner R, Wolfsgruber S, Dahmen N, Maier W, Wagner M, Quednow BB (2013). The effect of nicotine on sensorimotor gating is modulated by a CHRNA3 polymorphism. Psychopharmacology. 229(1):31-40.


8.    Perkins AM, Cserjesi R, Ettinger U, Kumari V, Martin NG, Arden R (2013). Personality and occupational markers of 'solid citizenship' are associated with having fewer children. Personality and Individual Differences. 55(8):871-876.


9.    Perkins AM, Leonard A, Krueger K, Dalton J, Mehta MA, Kumari V, Williams SCR, Ettinger U (2013). A dose of ruthlessness: interpersonal moral judgment is hardened by the anti-anxiety drug lorazepam. Journal of Experimental Psychology: General. 142(3):612-20.


10.    Perkins AM, Ettinger U, Weaver K, Schmechtig A, Schrantee A, Morrison PD, Sapara A, Kumari V, Williams SCR, Corr PK (2013). Advancing the defensive explanation for anxiety disorders: lorazepam effects on human defense are systematically modulated by personality and threat-type. Translational Psychiatry, 3, e246. doi: 10.1038/tp.2013.20.


11.    Wöstmann NM, Aichert DS, Costa A, Rubia K, Möller HJ, Ettinger U (2013). Reliability and plasticity of response inhibition and interference control. Brain and Cognition, 81(1), 82-94.


12.    Aichert DS, Derntl B, Wöstmann NM, Groß JK, Dehning S, Cerovecki A, Möller HJ, Habel U, Riedel M, Ettinger U (2013). Intact emotion-cognition interaction in schizophrenia patients and first-degree relatives: Evidence from an emotional antisaccade task. Brain and Cognition, 82(3), 329-336.


13.    Schmechtig A, Lees J, Perkins A, Altavilla A, Craig KJ, Dawson GR, Deakin JFW, Dourish CT, Evans LH, Koychev I, Weaver K, Smallman R, Walters J, Wilkinson LS, Morris R, Williams SCR, Ettinger U (2013). The Effects of Ketamine and Risperidone on Eye Movement Control in Healthy Volunteers. Translational Psychiatry. 3:e334. doi: 10.1038/tp.2013.109


14.    Ettinger U, Corr PJ, Mofidi A, Williams SCR, Kumari V (2013). Dopaminergic basis of the psychosis-prone personality investigated with functional magnetic resonance imaging of procedural learning. Frontiers in Human Neuroscience, Vol 7, Article 130.


15.    Schmechtig A, Lees J, Grayson L, Craig KJ, Dadhiwala R, Dawson GR, Deakin JFW, Dourish CT, Koychev I, McMullen K, Migo EM, Perry C, Wilkinson L, Morris R, Williams SCR, Ettinger U (2013). Effects of Risperidone, Amisulpride and Nicotine on Eye Movement Control and their Modulation by Schizotypy. Psychopharmacology, 227, 331-345.


16.    Antoniades C, Ettinger U, Gaymard B, Gilchrist I, Kristjansson A, Kennard C, Leigh J, Noorani I, Pouget P, Smyrnis N, Tarnowski A, Zee D, Carpenter RHS (2013). An internationally standardised antisaccade protocol for clinical use. Vision Research, 84, 1-5.


17.    Segal NL, Graham J, Ettinger U (2013). Unrelated Look-Alikes: A Replicated Study of Personality Similarity and New Qualitative Findings on Social Relatedness. Personality and Individual Differences, 55, 169-174.


18.    Costa A, Riedel M, Pogarell O, Menzel-Zelnitschek F, Schwarz M, Reiser M, Möller HJ, Rubia K, Meindl T, Ettinger U (2013). Methylphenidate effects on neural activity during response inhibition in healthy humans. Cerebral Cortex, 23, 1179-1189.


19.    Costa A, la Fougere C, Pogarell O, Möller HJ, Riedel M, Ettinger U (2013). Impulsivity is related to striatal dopamine transporter availability in healthy males. Psychiatry Research: Neuroimaging, 211, 251-256.


20.    Liepelt R, Schneider J, Aichert DS, Wöstmann N, Dehning S, Möller HJ, Riedel M, Dolk T, Ettinger U (2012). Action Blind: Disturbed Self-other Integration in Schizophrenia. Neuropsychologia, 50(14), 3775-3780.


21.    Macare C, Bates TC, Heath AC, Martin NG, Ettinger U (2012). Substantial genetic overlap between schizotypy and neuroticism: A twin study. Behavior Genetics, 42(5), 732-742.


22.    Aichert DS, Wöstmann NM, Costa A, Macare C, Wenig JR, Möller HJ, Rubia K, Ettinger U (2012). Associations between Trait Impulsivity and Prepotent Response Inhibition. Journal of Experimental and Clinical Neuropsychology, 34(10), 1016-1032.


23.    Allman AA, Ettinger U, Joober R, O'Driscoll GA (2012). Effects of methylphenidate on basic and higher-order oculomotor functions. Journal of Psychopharmacology, 26(11), 1471-1479.


24.    Völter C, Strobach T, Aichert DS, Wöstmann N, Costa A, Möller HJ, Schubert T, Ettinger U (2012). Schizotypy and behavioural adjustment and the role of neuroticism. PLoS ONE, 7(2), e30078.


25.    Völter C, Riedel M, Wöstmann N, Aichert D, Lobo S, Costa A, Schmechtig A, Collier DA, Hartmann AM, Giegling I, Möller HJ, Quednow BB, Rujescu D, Kumari V, Ettinger U (2012). Sensorimotor gating and D2 receptor signalling: evidence from a molecular genetic approach. International Journal of Neuropsychopharmacology, 15(10), 1427-1440.


26.    Aichert DS, Williams SCR, Möller HJ, Kumari V, Ettinger U (2012). Functional neural correlates of psychometric schizotypy: an fMRI study of antisaccades. Psychophysiology, 49(3), 345-356.


27.    Ettinger U, Williams SCR, Meisenzahl EM, Möller HJ, Kumari V, Koutsouleris N (2012). Association between brain structure and psychometric schizotypy in healthy individuals. World Journal of Biological Psychiatry, 13(7), 544-549.


28.    Petrovsky N, Ettinger U, Quednow BB, Walter H, Schnell K, Kessler H, Mössner R, Maier W, Wagner M (2012). Nicotine differentially modulates antisaccade performance in healthy male non-smoking volunteers stratified for low and high accuracy. Psychopharmacology, 221(1), 27-38.


29.    Premkumar P, Ettinger U, Inchley-Mort S, Sumich A, Williams SCR, Kuipers E, Kumari V (2012). Neural processing of social rejection: the role of schizotypal personality traits. Human Brain Mapping, 33(3), 695-706.


30.    Owens SF, Picchioni M, Ettinger U, McDonald C, Walshe M, Schmechtig A, Murray R, Rijsdijk F, Toulopoulou T (2012). Prefrontal deviations in function but not volume are putative endophenotypes for schizophrenia. Brain, 135(Pt 7), 2231-2244.


31.    Koychev I, McMullen K, Lees J, Dadhiwala R, Perry C, Schmechtig A, Walters J, Craig KJ, Dawson GR, Dourish CT, Ettinger U, Wilkinson L, Williams S, Deakin JFW, Barkus E (2012). A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-centre double-blind placebo-controlled study. European Neuropsychopharmacology, 22(7), 469-481.


32.    Ettinger U, Schmechtig A, Toulopoulou T, Borg C, Orrells C, Owens S, Matsumoto K, van Haren NE, Hall MH, Kumari V, McGuire PK, Murray RM, Picchioni M (2012). Prefrontal and striatal volumes in monozygotic twins concordant and discordant for schizophrenia. Schizophrenia Bulletin, 38(1), 192-203.


33.    Ettinger U, Williams SCR, Fannon D, Premkumar P, Kuipers E, Möller HJ, Kumari V (2011). Functional magnetic resonance imaging of a parametric working memory task in schizophrenia: relationship with performance and effects of antipsychotic treatment. Psychopharmacology, 216(1), 17-27.


34.    Costa A, Riedel M, Müller U, Möller HJ, Ettinger U (2011). Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human SPECT studies. Synapse, 65(10), 998-1005.


35.    Quednow BB, Ettinger U, Mössner R, Rujescu D, Giegling I, Collier DA, Schmechtig A, Kühn KU, Möller HJ, Maier W, Wagner M, Kumari V (2011). The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers. Journal of Neuroscience, 31(18), 6684-6691.


36.    Kempton MJ, Underwood TS, Brunton S, Stylios F, Schmechtig A, Ettinger U, Smith MS, Lovestone S, Crum WR, Frangou S, Williams SC, Simmons A (2011). A comprehensive testing protocol for neuroanatomical segmentation techniques: Evaluation of a novel lateral ventricle segmentation method. NeuroImage, 58(4), 1051-1059.


37.    Perkins AM, Ettinger U, Williams SCR, Reuter M, Hennig J, Corr PJ (2011). Flight behaviour in humans is intensified by a candidate genetic risk factor for panic disorder: evidence from a translational model of fear and anxiety. Molecular Psychiatry, 16(3), 242-244.


38.    Kempton M, Ettinger U, Foster R, Williams SCR, Calvert G, Hampshire A, Zelaya F, O’Gorman R, McMorris T, Owen AM, Smith M (2011). Dehydration affects brain structure and function in healthy adolescents. Human Brain Mapping, 32(1), 71-79.


39.    Hall MH, Taylor G, Sham P, Schulze K, Rijsdijk F, Picchioni M, Toulopoulou T, Ettinger U, Bramon E, Murray RM, Salisbury DF (2011). The early auditory gamma band response is heritable and a putative endophenotype of schizophrenia. Schizophrenia Bulletin, 37(4), 778-787.


40.    Koychev I, Barkus E, Ettinger U, Killcross S, Roiser J, Wilkinson L, Deakin JFW (2011) Evaluation of state and trait biomarkers in healthy volunteers for new drug treatments in schizophrenia. Journal of Psychopharmacology, 25, 1207-1225.


41.    Schmechtig A, Vassos E, Kumari V, Hutton SB, Collier DA, Morris RG, Williams SCR, Ettinger U (2010). Association of Neuregulin 1 rs3924999 genotype with antisaccades and smooth pursuit eye movements. Genes, Brain and Behavior, 9(6), 621-627.


42.    Borgwardt SJ, Picchioni M, Ettinger U, Toulopoulou T, Murray R, McGuire PK (2010). Gray matter volume in monozygotic twins with schizophrenia – a voxel-based morphometry study. Biological Psychiatry, 67(10), 956-964.


43.    Petrovsky N, Quednow BB, Ettinger U, Schmechtig A, Mössner R, Collier D, Kühn KU, Maier W, Wagner M, Kumari V (2010). Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacology, 35(7), 1429-1439.


44.    Crawford TJ, Hamm JP, Kean M, Schmechtig A, Kumari V, Anilkumar AP, Ettinger U (2010). The perception of real and illusory motion in schizophrenia. Neuropsychologia, 48(10), 3121-3127.


45.    Haraldsson HM, Ettinger U, Magnusdottir BB, Ingason A, Hutton SB, Sigmundsson T, Sigurdsson E, Petursson H (2010). Neuregulin-1 genotypes and eye movements in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 260(1), 77-85.


46.    Haraldsson HM, Ettinger U, Magnusdottir BB, Sigmundsson T, Sigurdsson E, Ingason A, Petursson H (2010). Catechol-O-methyltransferase Val 158 Met polymorphism and antisaccade eye movements in schizophrenia. Schizophrenia Bulletin, 36(1), 157-164.


47.    Perkins AM, Ettinger U, Davis R, Foster R, Williams SCR, Corr PJ (2009). Effects of lorazepam and citalopram on human defensive reactions: ethopharmacological differentiation of fear and anxiety. Journal of Neuroscience, 29(40), 12617-12624.


48.    Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Réthelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA; Genetic Risk and Outcome in Psychosis (GROUP), Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA (2009). Common variants conferring risk of schizophrenia. Nature, 460(7256), 744-747.


49.    Quednow BB, Schmechtig A, Ettinger U, Petrovsky N, Collier DA, Vollenweider FX, Wagner M, Kumari V (2009). Sensorimotor gating depends on polymorphisms of the 5-HT2A receptor and COMT, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biological Psychiatry, 66(6), 614-620.


50.    Ettinger U, Williams SCR, Patel D, Michel TM, Nwaigwe M, Caceres A, Mehta M, Anilkumar AP, Kumari V (2009). Effects of acute nicotine on brain function in healthy smokers and non-smokers: estimation of inter-individual response heterogeneity. NeuroImage, 45, 549-561.


51.    Petrovsky N, Schmechtig A, Flomen RH, Kumari V, Collier D, Makoff A, Wagner M, Ettinger U (2009). CHRFAM7A copy number and 2bp deletion polymorphisms and antisaccade performance. International Journal of Neuropsychopharmacology, 12, 267-273.


52.    Haraldsson HM, Ettinger U, Magnusdottir BB, Sigmundsson T, Sigurdsson E, Ingason A, Petursson H (2009). COMT val158met genotype and smooth pursuit eye movements in schizophrenia. Psychiatry Research, 169, 173-175.


53.    Hardoon D, Ettinger U, Mourao-Miranda J, Antonova E, Collier D, Kumari V, Williams SCR, Brammer M (2009). Correlation based multivariate analysis of genetic influence on brain volume. Neuroscience Letters, 450, 281-286.


54.    Petrovsky N, Weiss-Motz F, Schulze-Rauschenbach S, Lemke M, Hornung P, Ruhrmann S, Klosterkötter J, Maier W, Ettinger U, Wagner M (2009). Antisaccade performance is related to genetic loading for schizophrenia. Journal of Psychiatric Research, 43, 291-297.


55.    Kempton MJ, Ettinger U, Schmechtig A, Winter EM, Smith L, McMorris T, Wilkinson I, Williams SCR, Smith M (2009). Effects of acute dehydration on brain morphology in healthy humans. Human Brain Mapping, 30, 291-298.


56.    Rujescu D, Ingason A, Cichon S, Pietiläinen OPH, Barnes M, Toulopoulou T, Picchioni M, Vassos E, Ettinger U, Bramon E, Murray R, Ruggeri M, Tosato S, Bonetto C, Steinberg S, Sigurdsson E, Sigmundsson T, Petursson H, Gylfason A, Olason PI, Hardarsson G, Jonsdottir GA, Gustafsson O, Fossdal R, Giegling I, Möller HJ, Hartmann A, Hoffmann P, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Andreassen OA, Djurovic S, Hansen T, Werge T, Melle I, Kiemeney LA, Franke B, Buizer-Voskamp JE, Ophoff R, GROUP Investigators, Rietschel M, Noethen M, Stefansson K, Peltonen L, St Clair D, Stefansson H, Collier D (2009). Disruption of the neurexin 1 gene is associated with schizophrenia. Human Molecular Genetics, 18, 988-996.


57.    Ettinger U, Kumari V, Collier DA, Powell J, Luzi S, Michel TM, Zedomi O, Williams SCR (2008). Catechol-O-methyltransferase (COMT) val158met genotype is associated with brain activation as a function of task characteristic. Neuropsychopharmacology, 33, 3046-3057.


58.    Haraldsson HM, Ettinger U, Magnusdottir BB, Sigmundsson T, Sigurdsson E, Petursson H (2008). Eye movement deficits in schizophrenia: investigation of a genetically homogenous Icelandic sample. European Archives of Psychiatry and Clinical Neuroscience, 258, 373-383.


59.    Kempton MJ, Geddes JR, Ettinger U, Williams SCR, Grasby PM (2008). Meta-analysis, database and meta-regression of 98 structural imaging studies in bipolar disorder. Archives of General Psychiatry, 65, 1017-1032.


60.    Sumich A, Kumari V, Dodd P, Ettinger U, Hughes C, Zachariah E, Sharma T (2008). N100 and P300 amplitude to Go and No-Go variants of the auditory oddball in siblings discordant for schizophrenia. Schizophrenia Research, 98, 265-277.


61.    Ettinger U, ffytche DH, Kumari V, Kathmann N, Reuter B, Zelaya F, Williams SCR (2008). Decomposing the neural correlates of antisaccade eye movements using event-related fMRI. Cerebral Cortex, 18, 1148-1159.


62.    Ettinger U, Picchioni M, Landau S, Matsumoto K, Van Haren N, Marshall N, Hall MH, Schulze K, Toulopoulou T, Davies N, Ribchester T, McGuire PK, Murray RM (2007). Magnetic resonance imaging of the thalamus and adhesio interthalamica in twins with schizophrenia. Archives of General Psychiatry, 64, 401-409.


63.    Toulopoulou T, Picchioni M, Rijsdijk F, Hall MH, Ettinger U, Sham P, Murray R (2007). Substantial genetic overlap between neurocognition and schizophrenia: genetic modelling in twin samples. Archives of General Psychiatry. 64, 1348-1355.


64.    Hall MH, Rijsdijk F, Picchioni M, Schulze K, Ettinger U, Toulopoulou T, Bramon E, Murray RM, Sham P (2007). Substantial shared genetic influences on schizophrenia and event-related potentials. American Journal of Psychiatry. 164, 804-812.


65.    Ettinger U, Picchioni M, Hall MH, Schulze K, Toulopoulou T, Landau S, Crawford TJ, Murray RM (2006). Antisaccade performance in monozygotic twins discordant for schizophrenia: The Maudsley twin study. American Journal of Psychiatry, 163, 543-545.


66.    Ettinger U, Joober R, De Guzman R, O’Driscoll GA (2006). Schizotypy, attention deficit hyperactivity disorder features, and dopamine genes. Psychiatry and Clinical Neurosciences, 60, 764-767.


67.    Hall MH, Schulze K, Rijsdijk F, Picchioni M, Ettinger U, Bramon E, Freedman R, Murray RM, Sham P (2006). Heritability and reliability of P300, P50 and duration mismatch negativity. Behavior Genetics, 36(6), 845-857.


68.    Ettinger U, Hejda S, Flak V, Corr PJ (2005). Prepulse inhibition of the acoustic startle reflex and oculomotor control. Psychophysiology, 42(4), 473-482.


69.    Ettinger U, Antonova E, Crawford TJ, Mitterschiffthaler MT, Goswani S, Sharma T, Kumari V (2005). Structural neural correlates of antisaccade and prosaccade eye movements in healthy humans. NeuroImage, 24, 487-494.


70.    Ettinger U, Kumari V, Crawford TJ, Flak V, Sharma T, Davis RE, Corr PJ (2005). Saccadic eye movements, schizotypy, and the role of neuroticism. Biological Psychology, 68(1), 61-78.


71.    Kumari V, Das M, Zachariah E, Ettinger U, Sharma T (2005). Reduced prepulse inhibition in unaffected siblings of schizophrenia patients. Psychophysiology 42, 588-594.


72.    Kumari V, Antonova E, Zachariah E, Galea A, Aasen I, Ettinger U, Mitterschiffthaler MT, Sharma T (2005). Structural brain correlates of prepulse inhibition of the acoustic startle response in healthy humans. NeuroImage 26, 1052-1058.


73.    Hughes C, Kumari V, Das M, Zachariah E, Ettinger U, Sumich A, Sharma T (2005). Cognitive functioning in siblings discordant for schizophrenia. Acta Psychiatrica Scandinavica, 111(3), 185-192.


74.    Kumari V, Ettinger U, Crawford TJ, Zachariah E, Sharma T (2005). Lack of association between prepulse inhibition and antisaccadic deficits in chronic schizophrenia: Implications for identification of schizophrenia endophenotypes. Journal of Psychiatric Research, 39, 227-240.


75.    Ettinger U, Kumari V, Chitnis XA, Corr PJ, Crawford TJ, Fannon DG, O’Ceallaigh S, Sumich AL, Doku V, Sharma T (2004). Volumetric neural correlates of antisaccade eye movements in first-episode psychosis. American Journal of Psychiatry, 161, 1918-1921.


76.    Ettinger U, Kumari V, Crawford TJ, Corr PJ, Das M, Hughes C, Sumich AL, Zachariah E, Rabe-Hesketh S, Sharma T (2004). Smooth pursuit and antisaccade eye movements in siblings discordant for schizophrenia. Journal of Psychiatric Research, 38, 177-184.


77.    Das M, Kumari V, Soni W, Ettinger U, Binneman B, Hughes C, Mehrotra R, Sharma T (2004). Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia. Schizophrenia Bulletin, 30(2), 241-253.


78.    Ettinger U, Kumari V, Zachariah E, Galea A, Crawford TJ, Corr PJ, Taylor D, Das M, Sharma T (2003). Effects of procyclidine on eye movements in schizophrenia. Neuropsychopharmacology, 28, 2199-2208.


79.    Ettinger U, Kumari V, Crawford TJ, Davis RE, Sharma T, Corr PJ (2003). Reliability of smooth pursuit, fixation, and saccadic eye movements. Psychophysiology, 40, 620-628.


80.    Ettinger U, Kumari V, Chitnis XA, Corr PJ, Sumich AL, Rabe-Hesketh S, Crawford TJ, Sharma T (2002). Relationship between brain structure and saccadic eye movements in healthy humans. Neuroscience Letters, 328(3), 225-228.


81.    Ettinger U, Corr PJ (2001). The Frequency Accrual Speed Test (FAST): Psychometric intelligence and personality correlates. European Journal of Personality, 15(2), 143-152.


82.    Ettinger U, Chitnis XA, Kumari V, Fannon DG, Sumich AL, O’Ceallaigh S, Doku V, Sharma T (2001). Magnetic resonance imaging of the thalamus in first-episode psychosis. American Journal of Psychiatry, 158(1), 116-118.

 

 

Übersichtsarbeiten in referierten Zeitschriften

83.    Wright B, Peters E, Ettinger U, Kuipers E, Kumari V (in press). Understanding Noise Stress-Induced Cognitive Impairment and Its Implications for Schizophrenia. Noise & Health.


84.    Ettinger U, Meyhöfer I, Steffens M, Wagner M, Koutsouleris N (2014). Genetics, Cognition and Neurobiology of Schizotypal Personality: A Review of the Overlap with Schizophrenia. Frontiers in Psychiatry. 5:18.


85.    Haraldsson HM, Ettinger U, Sigurdsson E (2011). Developments in schizophrenia genetics: from linkage to microchips, deletions and duplications. Nordic Journal of Psychiatry, 65(2), 82-88.


86.    Hutton SB, Ettinger U (2006). The antisaccade task as a research tool in psychopathology: A critical review. Psychophysiology, 43, 302-313.


87.    Mitterschiffthaler MT, Ettinger U, Mehta MA, Mataix-Cols D, Williams SCR (2006). Applications of functional magnetic resonance imaging in psychiatry. Journal of Magnetic Resonance Imaging, 23, 851-861.


88.    Ettinger U, Kumari V (2003). Pharmacological studies of smooth pursuit and antisaccade eye movements in schizophrenia: current status and directions for future research. Current Neuropharmacology, 1(4), 285-300.

 

 

Andere Publikationen

89.    Ettinger U (in press). Gehirn und Geist. Chapter in Kühnhardt L, Mayer T (Ed.), Bonner Enzyklopädie der Globalität.


90.    Ettinger U, Klein C (in press). Eye Movements. Chapter in Reuter M, Montag C (Ed.), Neuroeconomics, Berlin: Springer Verlag.


91.    Mohr C, Ettinger U (in press). The role of dopamine in schizotypy. Chapter in Mason O, Claridge G (Ed.), Schizotypy: New Dimensions, Routledge.


92.    Migo E, Williams SCR, Crum W, Kempton M, Ettinger U (2011). The role of neuroimaging biomarkers in personalised medicine for neuro-degenerative and psychiatric disorders. Chapter 3 in Gordon E, Koslow SH (Ed.), Integrative Neuroscience and Personalized Medicine, Oxford University Press, pp. 141-163.


93.    Kumari V, Ettinger U (2010). Latent inhibition in schizophrenia and schizotypy: a review of the empirical literature. Chapter 17 in Lubow R, Weiner I (Ed.), Latent Inhibition: Cognition, Neuroscience, and Applications to Schizophrenia, Cambridge University Press, pp. 419-447.


94.    Klein C, Ettinger U (2008). A hundred years of eye movement research in psychiatry. Brain and Cognition, 68, 215-218. (Editorial)


95.    Kumari V, Ettinger U (2005). Prepulse inhibition deficits in schizophrenia: Static or amenable to treatment? Chapter 6 in Lang MV (Ed.), Trends in Schizophrenia Research, Nova Science Publishers, pp. 95-117.


96.    Ettinger U (2002). Review of the 11th World Congress of Psychophysiology. Journal of Advances in Schizophrenia and Brain Research, 4(4), 146-147.

 

 

Vorträge

1.    Die Rolle der Okulomotorik in der Kognitionsforschung. Eingeladener Vortrag, Centre for Economics and Neuroscience, Universität Bonn, November 2013


2.    Oculomotor Endophenotypes. European Summer School on Eye Movements, Bonn, September 2013


3.    Neuroimaging, Cognitive and Pharmacological Studies of Schizotypal Personality: Evidence of a Continuum with Schizophrenia? Eingeladener Vortrag, Department of Psychiatry, National University, Athen, Griechenland, März 2013


4.    Neuroimaging, Cognitive and Pharmacological Studies of Schizotypal Personality: Evidence of a Continuum with Schizophrenia? Robert Sommer Award Symposium, Gießen, Februar 2013

5.    Cognitive and Neural Effects of Acute Methylphenidate in Healthy Humans. DGPPN, Berlin, November 2012

6.    Effects of Nicotine and Antipsychotics on Cognitive Control: The Role of Schizotypy. DGPPN, Berlin, November 2012

7.    Neurocognitive Studies of Intra-subject Variability. 48. Kongress der Deutschen Gesellschaft für Psychologie, Bielefeld, September 2012

8.    Effects of Risperidone, Amisulpride and Nicotine on Antisaccade Eye Movements and their Modulation by Schizotypy. 48. Kongress der Deutschen Gesellschaft für Psychologie, Bielefeld, September 2012

9.    fMRI Ergebnisse zur Neurokognition schizophrener Erkrankungen. Abschiedssymposium zu Ehren von Herrn Prof. Dr. H.-J. Möller, LMU München, Juli 2012

10.    Neural Mechanisms of Cognitive Enhancement. Eingeladener Vortrag, Bonner Imaging Seminar, Universität Bonn, Mai 2012

11.    Neurocognitive Approaches to Schizotypal Personality. Eingeladener Vortrag, Klinik für Epileptologie, Universität Bonn, Mai 2012

12.    Pharmacological Influences on Oculomotor Control in Healthy Humans. Vision Sciences Society, Naples, USA, Mai 2012

13.    Neurocognitive Mechanisms of Inhibitory Control. TeaP, Mannheim, April 2012

14.    DFG Emmy Noether-Programm: Erfahrungsbericht. Workshop "Forschen in Europa: Nationale und europäische Forschungsförderung", LMU München, März 2012

15.    The Study of Oculomotor Control: Taking a Close Look at Cognition and Brain (Dys-)Function. Eingeladener Vortrag, Klinik für Psychiatrie, Universität Bonn, Februar 2012

16.    Neurocognitive Approaches to Schizotypal Personality. Eingeladener Vortrag, Klinik für Psychiatrie und Psychotherapie, Erlangen, Februar 2012

17.    Effects of Methylphenidate on Cognition and Brain Function. Eingeladener Vortrag, Institute of Psychiatry, London, UK, Januar 2012

18.    Neurokognitive Untersuchungen der Schizotypie. Eingeladener Vortrag, Klinik für Psychiatrie, LMU München, Januar 2012

19.    Neurokognitive Mechanismen der Inhibitionsfähigkeit. Ringvorlesung Kognitionswissenschaft, Institut für Psychologie, Humboldt-Universität zu Berlin, November 2011

20.    Methylphenidate Effects on Neural Activity during Response Inhibition in Healthy Humans. AGNP Tagung, München, Oktober 2011

21.    Neurokognitive Untersuchungen schizotyper Persönlichkeit. Symposium zu Ehren von Prof. Dr. Rolf Engel, LMU München, Oktober 2011

22.    Die Rolle des Neurotizismus in der Assoziation zwischen Schizotypie und Kognition. DPPD Fachgruppentagung, Saarbrücken, September 2011

23.    Genetic and Neuroimaging Studies of Antisaccades in the Schizophrenia Spectrum. European Conference on Eye Movements, Marseille, Frankreich, August 2011

24.    Biological Approaches to the Study of Schizotypal Personality. Conference of the International Society for the Study of Individual Differences, London, UK, Juli 2011

25.    Neurokognitive Untersuchungen der Schizotypie. Eingeladener Vortrag, Universitätsklinikum Ulm, Juli 2011

26.    Einfluss von Methylphenidat auf die neuronalen Korrelate der Inhibitionsfähigkeit. Tagung Psychologie & Gehirn, Heidelberg, Juni 2011

27.    Auswirkungen von Methylphenidat auf die Okulomotorik bei gesunden Probanden. Tagung Psychologie & Gehirn, Heidelberg, Juni 2011

28.    Neurobiological Approaches to the Study of Schizotypal Personality. Eingeladener Vortrag, Klinik für Psychiatrie und Psychotherapie, Universität Magdeburg, Mai 2011

29.    Neurocognitive Approaches to the Study of Schizotypal Personality. Eingeladener Vortrag, Department of Psychology, University of East London, UK, April 2011

30.    Einsatz von Stimulanzien: Neurobiologische Effekte. EEG-Tage, München, Februar 2011

31.    Methylphenidat: Auswirkungen auf Kognition und Gehirnfunktion. Eingeladener Vortrag, Klinik für Kinder- und Jugendpsychiatrie, Universität Freiburg, Januar 2011

32.    Genetic Studies of Neurophysiological Phenotypes in Schizophrenia. DGPPN, Berlin, November 2010

33.    Functional Magnetic Resonance Imaging of a Parametric Working Memory Task in Schizophrenia: Relationship with Performance and Effects of Antipsychotic Treatment. DGPPN, Berlin, November 2010

34.    Genetic and neuroimaging studies of eye movements. Symposium on Clinical Neurophysiology of Vision and on Eye Movements, Ljubljana, Slowenien, September 2010

35.    Behavioural and Molecular Genetic Studies of Cognitive and Oculomotor Phenotypes. Eingeladener Vortrag, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Juni 2010

36.    Molecular and behavioural genetic studies of oculomotor, cognitive and neuroimaging phenotypes. Eingeladener Vortrag, Abteilung Allgemeine Psychologie, Justus-Liebig-Universität Giessen, Juni 2010

37.    Okulomotorische Endophänotypen der Schizophrenie. Tagung Psychologie und Gehirn, Greifswald, Juni 2010

38.    Endophänotypen der Schizophrenie: Okulomotorik und Neuroimaging. Eingeladener Vortrag, Psychiatrische Poliklinik der Universität Basel, Schweiz, März 2010

39.    Neurobiologische Effekte von Methylphenidat bei Gesunden und Patienten, EEG-Tage, München, Februar 2010

40.    Oculomotor (Endo-)Phenotypes and Biomarkers. Eingeladener Vortrag, Institut für Medizinische Psychologie, Ludwig-Maximilians-Universität, München, Januar 2010

41.    Are endophenotypes the end of phenotypes? Cognitive Neuropsychiatry Conference, Bremen, November 2009

42.    Effects of acute nicotine on brain function in healthy smokers and non-smokers: Estimation of inter-individual response heterogeneity. AGNP Tagung, München, Oktober 2009

43.    Eye movements in schizophrenia: Recent evidence from genetics and neuroimaging. Hauptvortrag, British Ocular Motor Group Annual Meeting, Liverpool, UK, Januar 2009

44.    The role of psychology in brain science. Eingeladener Vortrag, Wycombe Abbey School, High Wycombe, UK, Dezember 2008

45.    Imaging and oculomotor endophenotypes of schizophrenia. Eingeladener Vortrag, Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, London, UK, Oktober 2008

46.    Psychophysiologische und bildgebende Endophänotypen der Schizophrenie. Eingeladener Vortrag, Klinik für Psychiatrie und Psychotherapie der Universitätsmedizin Göttingen, Oktober 2008

47.    Effects of nicotine on brain function during saccadic eye movements. XXVI CINP Congress, München, July 2008

48.    Imaging and pharmacological studies of oculomotor inhibition. 16th European Congress of Psychiatry, Nizza, Frankreich, April 2008

49.    Genetic and neuroimaging studies of antisaccade eye movements in schizophrenia. 16th European Congress of Psychiatry, Nizza, Frankreich, April 2008

50.    Psychology careers. Eingeladener Vortrag, John Hampden Grammar School, High Wycombe, UK, März 2008

51.    Genetic and neuroimaging studies of oculomotor endophenotypes in schizophrenia. Eingeladener Vortrag, Klinik für Psychiatrie und Psychotherapie, RWTH Aachen, Januar 2008

52.    Genetic and neuroimaging studies of oculomotor endophenotypes in schizophrenia. Eingeladener Vortrag, Institut für Psychologie, Universität Würzburg, Würzburg, Januar 2008

53.    Genetic and brain imaging studies of schizophrenia – the role of psychology. Eingeladener Vortrag, Eton College Psychological Society, Eton, UK, Oktober 2007

54.    Genetic and Neuroimaging Studies of Oculomotor Endophenotypes. 1st European Conference on Schizophrenia Research, Düsseldorf, September 2007

55.    Genetic and neuroimaging studies of eye movements in schizophrenia. Eingeladener Vortrag, Kneesworth House Hospital, Royston, UK, Mai 2007

56.    Einfluss von Nikotin auf Hirnaktivierung während einer okulomotorischen Arbeitsgedächtnisaufgabe bei gesunden Männern. Tagung experimentell arbeitender Psychologen (TeaP), Trier, März 2007

57.    Look away! Genetic and neuroimaging studies of antisaccade eye movements in schizophrenia. Eingeladener Vortrag, School of Psychology, Birkbeck College, London, UK, März 2007

58.    Look away! Genetic and neuroimaging studies of antisaccade eye movements in schizophrenia. Eingeladener Vortrag, Department of Psychology, University of Wales, Bangor, UK, März 2007

59.    Look away! Genetic and neuroimaging studies of antisaccade eye movements in schizophrenia. Neuroimaging Meeting, Institute of Psychiatry, London, Februar 2007

60.    Careers for Psychology PhD's: Academia & Beyond. Panel discussant, Higher Education Academy Psychology Network. Southbank University, London, Dezember 2006

61.    Relationship between prepulse inhibition and oculomotor control in schizophrenia. Cognitive Neuropsychiatry Congress, Bremen, Dezember 2006

62.    Look Away! Genetic and neuroimaging studies of antisaccade eye movements. Eingeladener Vortrag, Institut für Psychologie, Ludwig-Maximilians-Universität, München, November 2006

63.    Response inhibition and generation in the antisaccade task: an event-related fMRI study. Society for Psychophysiological Research, Vancouver, Kanada, Oktober 2006

64.    Magnetic resonance imaging of the thalamus and adhesio interthalamica in twins with schizophrenia. Deutsche Gesellschaft für Biologische Psychiatrie, München, Oktober 2006

65.    Oculomotor deficits as endophenotypes for schizophrenia. Eingeladener Vortrag, Psychiatrische Universitätsklinik, Bonn, März 2006

66.    Antisakkadendefizite bei Schizophrenie. Tagung Experimentell Arbeitender Psychologen, Mainz, März 2006

67.    Antisakkadendefizite bei Angehörigen und Zwillingen von Schizophrenen. Deutsche Gesellschaft für Psychiatrie, Psychotherapie, und Nervenheilkunde Congress, Berlin, November 2005

68.    Taking a close look at schizophrenia: Genetic, pharmacological and neuroimaging studies of antisaccade eye movements. Eingeladener Vortrag, Department of Psychology, University of Wales, Swansea, UK, Oktober 2005

69.    Taking a close look at schizophrenia: Genetic, pharmacological and neuroimaging studies of antisaccade eye movements. Eingeladener Vortrag, Department of Psychology, Thames Valley University, London, UK, März 2005

70.    Taking a close look at schizophrenia: Eye movement tasks as tools in genetic, pharmacological and neuroimaging studies. Eingeladener Vortrag, Max-Planck-Institut für Hirnforschung, Frankfurt, Juni 2004

71.    Antisaccades, schizotypy, and the role of neuroticism. 11th Biennial Meeting of the International Society for the Study of Individual Differences, Graz, Austria, Juli 2003

72.    Eye movement endophenotypes in genetic and pharmacological studies of schizophrenia. Eingeladener Vortrag, Broadmoor Hospital, Crowthorne, UK, Juli 2003

73.    Eye movements in schizophrenia: Current status and directions for future research. Eingeladener Vortrag, Institut für Psychologie, Humboldt-Universität zu Berlin, Berlin, Juli 2003

74.    Eye movements in schizophrenia: Current status and directions for future research. Eingeladener Vortrag, Klinik für Neurologie II, Otto-von-Guericke-Universität Magdeburg, Magdeburg, Juli 2003

75.    Eye movements in schizophrenia: Current status and directions for future research. Eingeladener Vortrag, Affective Neuroscience Group, Department of Psychology, Goldsmiths College, London, UK, Mai 2003

76.    Eye movements as schizophrenia endophenotypes. Eingeladener Vortrag, Division of Psychiatry, Landspitali University Hospital, Reykjavik, Island, November 2002

77.    Smooth pursuit and antisaccade eye movements in siblings discordant for schizophrenia. Eingeladener Vortrag, Departement de Psychiatrie Générale, Université de Lille II, Lille, Frankreich, Juni 2002

78.    Smooth pursuit and antisaccade eye movements in siblings discordant for schizophrenia. Psychosis Interest Group, Institute of Psychiatry, London, UK, Mai 2002

79.    Eye movements and the genetics of schizophrenia. Eingeladener Vortrag, Department of Clinical Psychology, Northwick Park Hospital, London, UK, März 2002

80.    Neural correlates of saccadic eye movements in first-episode psychosis. 13th Annual Meeting of the British Ocular Motor Group, Imperial College, London, UK, Dezember 2001

82.    First-episode psychosis, magnetic resonance imaging, and saccadic eye movements. Section of Cognitive Psychopharmacology Symposium, Institute of Psychiatry, London, UK, April 2001

83.    Structural MRI correlates of saccade and antisaccade performance in healthy and schizophrenic subjects. The First Irish Workshop on Eye-Tracking, Trinity College Dublin, Irland, May 2000

84.    Psychometric intelligence, personality, and neural correlates of Frequency Accrual Speed Test (FAST) performance. Eingeladener Vortrag, Mathematical Cognition Group, Department of Human Communication Science, University College London, UK, Februar 2000

85.    Psychometric intelligence, personality, and neural correlates of Frequency Accrual Speed Test (FAST) performance. British Psychophysiology Society 27th Annual Meeting, Institute of Neurology, London, UK, Dezember 1999

86.    Mental speed, intelligence, and personality. British Psychological Society Annual Conference, Student Group, Belfast, UK, April 1999

87.    Klassische und IRT-Itemanalysen bei Leistungs- und Persönlichkeitstests. Seminar Aktuelle Probleme psychiatrischer Forschung aus psychologischer Sicht, Psychiatrische Klinik der LMU München, Dezember 1998

88.    Mental speed, intelligence, and personality. BAAS Annual Festival of Science, Cardiff, UK, September 1998

 

 

Organisation von Symposien und Workshops

1.    "Experimentelle und klinische Untersuchungen des Dopamin-Systems". AGNP, München, September 2013

2.    "European Summer School on Eye Movements". Bonn, September 2013

3.    "Nicotine as a cognitive enhancer". DGPPN, Berlin, November 2012

4.    "Neuromodulation of Visual Perception". Vision Sciences Society, Naples, USA, May 2012

5.    "Cognitive Control: Experimental Psychology and Cognitive Neuroscience". TeaP, Mannheim, April 2012

6.    "Integrating Philosophy and Neuroscience in the Study of Consciousness: How to Make it Work". Centre for Advanced Studies, LMU München, Dezember 2011

7.    "Interindividuelle Differenzen von Emotionalität: Neue Befunde aus Genetik und Experimentalpsychologie". DPPD Fachgruppentagung, Saarbrücken, September 2011

8.    "Neuroscientific approaches to personality: from basic research to clinical implications". Conference of the International Society for the Study of Individual Differences, London, UK, Juli 2011

9.    "Neuere Entwicklungen in der Pharmakopsychologie". Tagung Psychologie & Gehirn, Heidelberg, Juni 2011

10.    "The intermediate phenotype strategy in schizophrenia and psychotic bipolar disorder”. DGPPN, Berlin, November 2010

11.    "Treatment Effects on Cognition and Brain Function in Schizophrenia”. DGPPN, Berlin, November 2010

12.    "Molecular Genetics and Neuroscience II”. Tagung Psychologie und Gehirn, Greifswald, Juni 2010

13.    "Structural and functional imaging of the brain in twins with schizophrenia”. European Psychiatric Association, München, Februar 2010

14.    "Neuropsychobiology of inhibitory deficits in schizophrenia: an update”. 16th European Congress of Psychiatry, Nizza, France, April 2008

15.    "Psychopharmakologie und Experimentalpsychologie". Tagung experimentell arbeitender Psychologen (TeaP), Trier, März 2007

16.    "Neural correlates of oculomotor control: basic and clinical research”. Society for Psychophysiological Research, Vancouver, Kanada, Oktober 2006

17.    "Experimentalpsychologische Ansätze in der Schizophrenieforschung”. Tagung Experimentell Arbeitender Psychologen, Mainz, März 2006

18.    "Augenbewegungen als Indikatoren für Störungen kortikaler Netzwerke bei psychiatrischen Störungen”. Deutsche Gesellschaft für Psychiatrie, Psychotherapie, und Nervenheilkunde Congress, Berlin, November 2005

19.    "Symposium of the Section of Cognitive Psychopharmacology". Institute of Psychiatry, London, UK, April 2001

 

Artikelaktionen